Recommended OCP Dosing for Polycystic Ovary Disorder (PCOD)

First-Line OCP Options for PCOD

The American Academy of Family Physicians recommends low-dose combined oral contraceptives containing 30-35 μg of ethinyl estradiol as the initial treatment choice for women with PCOD who are not attempting to conceive 1
COCs with progestins such as levonorgestrel or norgestimate are commonly used in clinical practice for PCOD management, as suggested by the American Academy of Pediatrics 2

Combined oral contraceptives suppress ovarian androgen secretion and increase sex hormone binding globulin levels, effectively reducing circulating free androgens, according to the American Academy of Family Physicians 1
Regular use of COCs provides endometrial protection, reducing the risk of endometrial cancer in women with PCOD, as recommended by the American Academy of Family Physicians 1
COCs restore regular menstrual cycles, improving the irregular bleeding patterns common in PCOD, as stated by the American Academy of Family Physicians 1
Treatment with COCs has been associated with improvements in hirsutism and acne in women with PCOD, according to the American Academy of Family Physicians 3

Standard dosing involves 21 days of active hormone pills followed by 7 days of placebo pills, though extended or continuous regimens may be used, as suggested by the American Academy of Pediatrics 2
Extended cycle formulations or continuous formulations may be beneficial for some patients with PCOD, as recommended by the American Heart Association 4

COCs containing ethinyl estradiol are associated with an increased risk of venous thromboembolism, with risk varying by progestin type, according to the American Heart Association 4
The absolute risk of VTE with COC use remains lower than the risk associated with pregnancy, as stated by the American Academy of Pediatrics 2
Blood pressure should be monitored, as approximately 10% of reproductive-aged women have elevated blood pressure, and OCPs can potentially affect blood pressure, as recommended by the American Heart Association 4

For women with contraindications to estrogen-containing contraceptives, progestin-only options or non-hormonal approaches may be considered, as suggested by the American Academy of Pediatrics 2
Weight loss of as little as 5% of initial body weight can improve metabolic and reproductive abnormalities in PCOD and should be encouraged alongside pharmacological management, according to the American Academy of Family Physicians 3
Insulin-sensitizing agents such as metformin may be beneficial for improving insulin sensitivity and ovulation rates in women with PCOD, as recommended by the American Academy of Family Physicians 5